Picture of mobile phone running fintech app

Fintech: Open Access research exploring new frontiers in financial technology

Strathprints makes available Open Access scholarly outputs by the Department of Accounting & Finance at Strathclyde. Particular research specialisms include financial risk management and investment strategies.

The Department also hosts the Centre for Financial Regulation and Innovation (CeFRI), demonstrating research expertise in fintech and capital markets. It also aims to provide a strategic link between academia, policy-makers, regulators and other financial industry participants.

Explore all Strathclyde Open Access research...

A new ceramide along with eight known compounds from the roots of Artemisia incisa pamp

Mamoon-Ur-Rashid, and Alamzeb, Muhammad and Ali, Saqib and Khan, Ashfaq Ahmad and Igoli, John O and Ferro, Valerie A and Gray, Alexander Irvine and Khan, Mohammad Rafiullah (2015) A new ceramide along with eight known compounds from the roots of Artemisia incisa pamp. Records of Natural Products, 9 (3). pp. 297-304. ISSN 1307-6167

[img]
Preview
Text (Mamoon-Ur-Rashid-etal-RNP-2015-A-new-ceramide-along-with-eight-known-compounds)
Mamoon_Ur_Rashid_etal_RNP_2015_A_new_ceramide_along_with_eight_known_compounds.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (599kB) | Preview

Abstract

A new compound (1) (named as artemceramide-B) together with eight known compounds (taraxerol (2), taraxerol acetate (3), β-sitosterol (4), stigmasterol (5), trans-ethyl caffeate, dracunculin (7), scoparone (8) and isoscopoletin (9) were isolated from an ethanolic extract of the roots of Artemisia incisa Pamp (Asteracae). The structures of the compounds were determined through IR, 1D NMR (1H NMR, 13C NMR) and 2D NMR (COSY, NOESY, HSQC and HMBC) analyses. Accurate mass analyses were done with EI-MS, ESI-MS and acid methanolysis of compound 1 followed by GS-MS studies. The relative stereochemistry of artemceramide-B was determined by comparing its specific rotation and spectroscopic data with the literature. Compounds 1-9 were tested for their anti-bacterial potential against five bacteria strains; Staphylococcus epidermidis, Staphylococcus aureus, Klebsiella pneumoniae, Bacillus subtilis and Escherichia coli. Compound 1 (new) (MIC: 0.0157, 0.0313 mg/mL) and 7 (MIC: 0.0815 , 1.000 mg/mL) showed excellent activities against S. epidermidis and S. aureus while compound 9 showed excellent activities (MIC: 0.0700 , 1.234, 1.890 and 2.286 mg/mL) against S. epidermidis,S. aureus, K. pneumoniae and E. coli, respectively. Compound 6 (MIC: 2.000 mg/mL) was found to be active against E. coli while neither of the compounds showed potential activity against B. subtilis.